Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | LIPE | Q05469 | 3/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 4/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | F13A1 | P00488 | 2/20 | 0.38 |
| ▸ | TGM2 | P21980 | 2/20 | 0.38 |
| ▸ | TGM1 | P22735 | 1/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25253992 | 0.87 | CHRM1 (0.48) | CHRM1LIPEAKR1C3SPRKDM2B | |
| SCHEMBL25296793 | 0.81 | LIPE (0.46) | LIPEGPR119F13A1TGM2TGM1 | |
| SCHEMBL25292247 | 0.79 | MGLL (0.45) | LIPEAKR1C3KDM2BRORCGPR119 | |
| SCHEMBL30488780 | 0.79 | MGLL (0.45) | LIPEAKR1C3KDM2BRORCGPR119 | |
| SCHEMBL25253193 | 0.78 | LIPE (0.44) | CHRM1LIPEAKR1C3SPRKDM2B | |
| SCHEMBL30409361 | 0.77 | MGLL (0.43) | CHRM1LIPEAKR1C3SPRKDM2B | |
| SCHEMBL30409535 | 0.77 | CHRM1 (0.40) | CHRM1LIPEAKR1C3SPRRORC | |
| SCHEMBL29497041 | 0.76 | EPHX2 (0.48) | SPRRORCPARP1GPR119F13A1 | |
| SCHEMBL23850527 | 0.76 | EPHX2 (0.48) | SPRRORCPARP1GPR119F13A1 | |
| SCHEMBL25298280 | 0.75 | HSD11B1 (0.49) | RORCGPR119F13A1TGM2TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| CN-115989228-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | CBR3, BRIX1, CCNY | CHRM1 758/4885LIPE 2733/4885AKR1C3 159/4885 |
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | CHRM1 758/4885LIPE 2733/4885AKR1C3 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.